Methodology

All entries for: Novartis

July 8, 2026

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

“In its largest layoff round this year, Novartis is cutting its East Hanover, New Jersey, workforce for a fourth time, letting go of 322 employees and bringing the site’s total to 572. The cuts take effect Oct. 2, per a WARN Act notice.

The first three rounds at the Swiss pharma’s East Hanover site were disclosed in March, April and May, affecting 114, 60 and 76 employees respectively. All are effective this year.

In total, Novartis has announced or disclosed at least 792 job cuts in 2026. In May, the company confirmed to BioSpace it was laying off a select number of staff in its biomedical research arm. That same month, it announced the closure of a production site in Wehr, Germany by the end of 2028, eliminating 220 jobs.”

Disease Area: Cardiology, Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
Source
Source
May 22, 2026

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

Novartis is continuing to trim its workforce in the U.S., letting go of 76 employees in East Hanover, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state. The layoffs will take effect on Aug. 21.

This will be the third time this year that Novartis downsized its New Jersey operations. The first batch of layoffs was announced in March, affecting 114 employees set to take effect from June 26 through Nov. 27. The second hit came a month later, with 60 jobs projected to be cut from July 24 through Nov. 20.

Novartis earlier this month also announced that it would close down a production site in Germany by the end of 2028, eliminating 220 jobs in the process.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple
Drug Type: Biologic, Small Molecule
Source
Source
May 15, 2026

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

Novartis is letting go of “a select number” of employees within its biomedical research organization, a company spokesperson confirmed to BioSpace in an emailed statement.

“Novartis continually assesses opportunities to support our growth strategy as a focused innovative medicines company,” the statement read. “We regularly evaluate our organizational setup to ensure it remains aligned with evolving priorities.”

The cuts are the latest in a series of made or projected layoffs at Novartis this year that in total affect nearly 400 employees. Earlier this month, the Swiss pharma announced plans to shutter a production facility in Wehr, Germany, by the end of 2028. Novartis expects that closure will eliminate 220 jobs. In March and April, the pharma disclosed between two Worker Adjustment and Retraining Notification (WARN) Act notices that it will let go of 174 employees in East Hanover, New Jersey. Of those cuts, layoffs affecting 114 people are effective June 26 through Nov. 27, while those impacting 60 staffers run from July 24 through Nov. 20.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
Source
May 8, 2026

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

Novartis plans to close a production facility in Wehr, Germany, by the end of 2028, a move that’s expected to eliminate 220 jobs, the Swiss pharma announced May 5.

The site, which makes solid oral dosage forms such as tablets and capsules for mostly established Novartis products, is no longer competitive, the company noted in its announcement. Novartis said it remains committed to Germany as a business location.

The pharma is investing 35 million euros (about $41 million) into a new production facility for radioligand therapies in Halle, Germany. The site will produce personalized cancer therapies for patients in Germany and should be operational in 2027, according to the announcement.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
Source
April 28, 2026

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

For the second month in a row, Novartis is chipping away at its East Hanover, New Jersey, workforce. The Swiss pharma is laying off 60 employees in the city effective July 24 to Nov. 20, according to a Worker Adjustment and Retraining Notification Act (WARN) notice. Novartis is also letting go of 114 people in East Hanover from June 26 to Nov. 27, according to a March WARN alert.

Novartis also trimmed its workforce in 2025, putting 1,069 employees—including 485 in East Hanover—on the chopping block over a multiyear period. The largest round of layoffs involved 550 employees in Switzerland who will be out of work by the end of 2027.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
Source
February 4, 2026

Novartis

Neutral Outlook

Basel, Baselstadt
10,000+ employees

Our business has continuously experienced significant pressures on the pricing of our products and on our ability to obtain and maintain satisfactory rates of reimbursement for our products from governments, insurers and other payers… For example, in May 2025, the US administration issued an executive order aiming to implement “most‑favored‑nation” pricing tying US prescription drug prices with prices in selected comparably developed nations.

Source
Source
November 25, 2025

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

Novartis will cut 550 full-time jobs at a facility in Switzerland by the end of 2027. The cuts come as the pharma company is ending production of tablets, capsules, and sterile medicine packaging at a plant in Stein, Switzerland.

Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
Source
April 10, 2025

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

Novartis disclosed two layoffs, with the largest one affecting 427 employees at its U.S. headquarters in East Hanover, New Jersey, and 34 employees in San Diego.

Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
Source
Source
March 19, 2025

Novartis - San Diego

Layoffs

San Diego, CA
10,000+ employees

Novartis is putting 34 more jobs on the chopping block, this time affecting employees at its Campus Point manufacturing facility in San Diego, California. According to the WARN notice posted March 13, the layoffs are in connection with the site’s closure and will be effective on June 27.

Disease Area: Oncology
Drug Type: Biologic, Small Molecule
Source
Source
May 19, 2023

Novartis

Discontinued Drug, Discontinued Research

Basel, Baselstadt
10,000+ employees

“In an interview with Barron’s, Narasimhan said some of the programs which Novartis discontinued were cancer drugs in early-stage trials.

“We saw assets that were noncompetitive, or we thought might be unduly affected by IRA,” Narasimhan said.

The CEO said “a few” of the cancer drugs being dropped from Novartis’s pipeline were discontinued because of price negotiations.

The drugs that were dropped were “in areas where we didn’t think we could do a development plan that would allow us to successfully get the drug in patients, and fully developed across the range of indications within nine years,” Narasimhan said. They were in cancers particularly affecting the elderly, given that Medicare treats adults aged 65 and older.”

2 Discontinued Drugs: unnamed cancer drugs
2 Discontinued Research Programs

Disease Area: Oncology
Drug Type: Biologic, Small Molecule
Source
Source
Scroll to Top